Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trialDNA 또는 NYVAC 벡터(HVTN 096)가 있는 외피 단백질을 포함하는 다가 HIV 백신의 안전성 및 면역원성: 1b상, 이중 맹검, 위약 대조 시험Article Published on 2019-10-072022-09-06 Journal: The Lancet. HIV [Category] Communicable Disease, [키워드] active treatment Administered administration adverse event allergy antibodies antibody Antibody Response Antibody responses antibody-dependent cell-mediated cytotoxicity approach assigned binding binding antibody boost Cell-mediated cytotoxicity Combination component computer-generated Coverage cranial cytotoxicity died DNA dose doses double-blind early administration effective Efficacy enrolled envelope protein epitope finding followed by foundation funding glycoprotein gp120 healthy healthy volunteer healthy volunteers HIV infection HIV vaccine IgG IgG response IgG responses immunogenicity individual Infection Infectious diseases injection Lymphadenopathy marker measure Melinda Gate Melinda Gates motor vehicle Neutralising Antibodies outcome participant Participants Placebo placebo group placebo-controlled placebo-controlled trial Primary outcomes priming product Protein purified random Randomly reactogenicity regimen Registered responses risk Safety screened Serious Adverse Event Serious Adverse Events Switzerland the placebo group the vaccine trauma Treatment treatment group treatment groups Trial trials vaccination vaccination schedule Vaccinations Vaccine vector Volunteer [DOI] 10.1016/S2352-3018(19)30262-0 PMC 바로가기 [Article Type] Article
Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial건강한 성인에서 HIV를 예방하기 위한 아데노 관련 바이러스 매개 면역 예방: 1상 무작위 대조 시험Article Published on 2019-03-152022-09-06 Journal: The Lancet. HIV [Category] Communicable Disease, [키워드] adeno-associated virus adverse event adverse events AIDS alternative analyses anti-drug antibody antibody assigned cassettes Clinical research Cohort Complete Consent detect development dose dose-escalation double-blind eligibility eligible ELISA expression finding Follow-up foundation funding Future gene delivery Gene Expression generally mild genomes groups healthy HIV HIV antibodies HIV infection immunisation induce initiative Intervention Intramuscular injection Melinda Gate Melinda Gates men moderate muscle biopsy neutralisation neutralisation activity neutralising Neutralising Antibodies neutralising antibody Phase 1 Placebo placebo-controlled Prevent provided public health quadricep quadriceps randomised randomised controlled trial Randomly reactogenicity receive Registered Research resolved RT-PCR screened Serious Adverse Event Serious Adverse Events serotype serum sustained T-cell Response T-cell responses Tolerability Trial United State United States Vaccine virus Volunteer volunteers was done were recorded [DOI] 10.1016/S2352-3018(19)30003-7 PMC 바로가기 [Article Type] Article
Cross-sectional surveillance of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels and other mammals in Egypt, August 2015 to January 2016Surveillance and Outbreak Report Published on 2017-03-162022-10-31 Journal: Eurosurveillance [Category] Coronavirus, Fulltext, MERS, 조류인플루엔자, [키워드] addition age antibody bat bats Camel Camel, Ruminants clade Cluster collected conducted Contact cross-sectional determine East Egypt Equines genetic material mammal MERS-CoV Middle East nasal swabs Neutralising Antibodies neutralising antibody positive Prevalence Rectal swabs respiratory syndrome coronavirus ruminant sampling sequence sera seropositive Seroprevalence significantly higher Surveillance tested titre Transmission virus [DOI] 10.2807/1560-7917.ES.2017.22.11.30487 PMC 바로가기 [Article Type] Surveillance and Outbreak Report